

CASE QA0253 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Laurelee A. Duncan
Type or print name

Laurelee A. Duncan
Signature

03/09/04
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BARBOSA ET AL.

APPLICATION NO: 10/702,295

FILED: NOVEMBER 6, 2003

FOR: FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-5323


Laurelee A. Duncan
Attorney for Applicants
Reg. No. 44,096

Date: 03/09/04

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
QA0253 NP
APPLICATION NO.
10/702,295
APPLICANT
BARBOSA ET AL.
FILING DATE
NOVEMBER 6, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,212,291	5/18/93	Murdock et al.			
	AB	5,527,896	6/18/96	Wigler et al.			
	AC	5,726,302	3/10/98	Ugarkar et al.			
	AD	5,733,913	3/31/98	Blankley et al.			
	AE	5,733,914	3/31/98	Blankley et al.			
	AF	5,977,305	11/2/99	Wigler et al.			
	AG	6,028,183	2/22/00	Lin et al.			
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	EP 0 767 172	4/9/97	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0 861 836	9/2/98	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 1 201 765	5/2/00	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AP	ES 2 009 145	9/1/89	ES			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	JP 58-150503	9/7/83	JP			<input type="checkbox"/>	<input type="checkbox"/>


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Han, P. et al., "Alternative Splicing of the High Affinity cAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart", The Journal of Biological Chemistry, Vol. 272, No. 26, pp. 16152-16157 (1997)
	AS	Henry, J.R. et al., "p38 mitogen-activated protein kinase as a target for drug discovery", Drugs of the Future, Vol. 24, No. 12, pp. 1345-1354 (1999)
	AT	Li, L. et al., "CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation", Science, Vol. 283, pp. 848-851 (1999)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



INFORMATION DISCLOSURE CITATION*(Use several sheets if necessary)*ATTY. DOCKET NO.
QA0253 NP
APPLICATION NO.
10/702,295
APPLICANT
BARBOSA ET AL.
FILING DATE
NOVEMBER 6, 2003

Group

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
	2AA	WO 98/13350	4/2/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AB	WO 98/33798	8/6/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AC	WO 01/28987	4/26/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AD	WO 01/44258	6/21/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AE	WO 01/55148	8/2/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AF	WO 01/64679	9/7/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
QA0253 NP
APPLICATION NO.
10/702,295
APPLICANT
BARBOSA ET AL.
FILING DATE
NOVEMBER 6, 2003

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Moreland, L.W. et al., "Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial", Ann. Intern. Med., Vol. 130, pp. 478-486 (1999)
3AB	Nakata, A. et al., "Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors", Clin. Exp. Immunol., Vol. 128, pp. 460-466 (2002)
3AC	Rankin, E.C.C. et al., "The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis", British Journal of Rheumatology, Vol. 34, pp. 334-342 (1995)
3AD	Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases", Current Medicinal Chemistry, Vol. 6, pp. 807-823 (1999)
3AE	Sasaki, T. et al., "Identification of Human PDE7B, a cAMP-Specific Phosphodiesterase", Biochemical and Biophysical Research Communications, Vol. 271, pp. 575-583 (2000)
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.